People who have a certain type of skin cancer may receive Zelboraf to help slow down the progression of this disease. This medicine is specifically designed for melanoma that cannot be treated with surgery or has spread to other areas of the body. It comes in tablet form and is taken twice a day. Side effects may include fatigue, hair loss, and joint pain.
What Is Zelboraf?
Zelboraf™ (vemurafenib) is a prescription medication approved to treat melanoma (a type of skin cancer) that cannot be treated with surgery or has spread to other areas of the body (metastasized). It is meant for use in people who have an abnormal BRAF V600E gene.
Zelboraf is made by Daiichi Sankyo, Inc., for Genentech USA, Inc.
How Does It Work?
Zelboraf is approved for use in people who have an abnormal gene known as the BRAF gene. The BRAF protein helps regulate cell growth. When the BRAF gene is abnormal, the BRAF protein is constantly turned on, causing an abnormal growth of cells, which leads to melanoma.
Zelboraf works by blocking the action of the BRAF protein, and thus preventing abnormal cell growth. By blocking abnormal cell growth, Zelboraf can slow down the progression of melanoma.
Zelboraf has been shown to improve survival time and delay progression of advanced melanoma in people who have not already received treatment. Everyone in the clinical study had a mutation in the BRAF gene, which is associated with melanoma.
In the study, people given Zelboraf had a progression-free survival (which is the amount of time after treatment starts that the cancer does not get worse) of about 5.3 months, compared to 1.6 months in people given a different cancer medication.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Zelboraf [package insert]. South San Francisco, CA: Genentech USA, Inc.;2014 March.
U.S. Food and Drug Administration. FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer (8/17/2011). FDA Web site. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm268241.htm. Accessed November 1, 2011.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed November 1, 2011.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click